Moomoo AI 已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, announced on January 8, 2024, the positive results from its Phase 1 studies of proprietary deuterated DMT molecules, CYB004 and SPL028. The studies, conducted on healthy volunteers, showed promising safety, pharmacokinetic (PK), and pharmacodynamic (PD) data, suggesting potential for these compounds in treating generalized anxiety disorder (GAD). CYB004, administered intravenously (IV), and SPL028, administered both IV and intramuscularly (IM), were well-tolerated with no serious adverse events. The IM administration of SPL028 produced robust, short-duration psychedelic effects, indicating a more convenient and patient-friendly dosing method. These results support the progression to a Phase 2 study in GAD, planned for Q1 2024. Cybin's patent portfolio includes 40 granted patents and over 170 pending applications, with 25 patents directly related to the deuterated DMT program. The company's CEO, Doug Drysdale, highlighted the significance of these first-in-human studies and the potential for IM dosing to inform future clinical trials. Cybin is focused on developing psychedelic-based treatments for mental health conditions and is also advancing CYB003, a deuterated psilocybin analog for major depressive disorder.
Cybin Inc., a clinical-stage biopharmaceutical company, announced on January 8, 2024, the positive results from its Phase 1 studies of proprietary deuterated DMT molecules, CYB004 and SPL028. The studies, conducted on healthy volunteers, showed promising safety, pharmacokinetic (PK), and pharmacodynamic (PD) data, suggesting potential for these compounds in treating generalized anxiety disorder (GAD). CYB004, administered intravenously (IV), and SPL028, administered both IV and intramuscularly (IM), were well-tolerated with no serious adverse events. The IM administration of SPL028 produced robust, short-duration psychedelic effects, indicating a more convenient and patient-friendly dosing method. These results support the progression to a Phase 2 study in GAD, planned for Q1 2024. Cybin's patent portfolio includes 40 granted patents and over 170 pending applications, with 25 patents directly related to the deuterated DMT program. The company's CEO, Doug Drysdale, highlighted the significance of these first-in-human studies and the potential for IM dosing to inform future clinical trials. Cybin is focused on developing psychedelic-based treatments for mental health conditions and is also advancing CYB003, a deuterated psilocybin analog for major depressive disorder.
處於臨床階段的生物製藥公司Cybin Inc. 於2024年1月8日宣佈了其對專有氘化DMT分子 CYB004 和 SPL028 的1期研究的積極結果。這些針對健康志願者的研究顯示出令人鼓舞的安全性、藥代動力學（PK）和藥效學（PD）數據，表明這些化合物有可能治療廣泛性焦慮症（GAD）。靜脈注射（IV）的 CYB004 和靜脈注射和肌肉注射（IM）的 SPL028 耐受性良好，沒有嚴重的不良事件。SPL028 的 IM 給藥產生了強大、持續時間短的迷幻效果，這表明給藥方法更方便、對患者更友好。這些結果支持計劃於2024年第一季度進行的GAD二期研究的進展。Cybin的專利組合包括40項已獲授權...展開全部
處於臨床階段的生物製藥公司Cybin Inc. 於2024年1月8日宣佈了其對專有氘化DMT分子 CYB004 和 SPL028 的1期研究的積極結果。這些針對健康志願者的研究顯示出令人鼓舞的安全性、藥代動力學（PK）和藥效學（PD）數據，表明這些化合物有可能治療廣泛性焦慮症（GAD）。靜脈注射（IV）的 CYB004 和靜脈注射和肌肉注射（IM）的 SPL028 耐受性良好，沒有嚴重的不良事件。SPL028 的 IM 給藥產生了強大、持續時間短的迷幻效果，這表明給藥方法更方便、對患者更友好。這些結果支持計劃於2024年第一季度進行的GAD二期研究的進展。Cybin的專利組合包括40項已獲授權的專利和170多項待處理的申請，其中25項專利與氘化DMT計劃直接相關。該公司首席執行官道格·德賴斯代爾強調了這些首次人體研究的重要性以及即時注射劑量爲未來的臨床試驗提供信息的可能性。Cybin專注於爲心理健康狀況開發基於迷幻藥的治療方法，並且還在推進 CYB003，這是一種用於重度抑鬱症的氘化迷幻藥類似物。
有用
沒用